Last month the government announced the launch of a COVID-19 Antivirals Taskforce to search for the most promising novel antiviral medicines that can be taken at home after a positive COVID-19 test result or prophylactically after exposure.
We gathered five experts on the development of antivirals (including several PIs on clinical trials investigating some of the potential candidates) to discuss the current situation in the UK, the process of antiviral drug development and the challenges of this project.
The panel are not associated with the COVID-19 Antivirals Taskforce and were not be able to answer questions about it directly, but they were able to address questions such as:
Prof Ian Hall, Professor of Molecular Medicine, University of Nottingham & Chair of the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP) antiviral sub-panel
Dr Ruth McKernan, Chair at BioIndustry Association
Prof Saye Khoo, Professor of Pharmacology and Therapeutics, University of Liverpool & Chief Investigator for the AGILE Coronavirus Drug Testing Initiative
Dr Daria Hazuda, Vice President – Research, Chief Scientific Officer, MSD
Prof Philip Bath, Professor of Stroke Medicine, University of Nottingham & lead researcher for PROTECT-CH